Beyond the monoaminergic hypothesis: Agomelatine, a new antidepressant with an innovative mechanism of action
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
There are many potentials for the development of more effective, better tolerated, and more rapidly acting antidepressants. As there is large prevalence of circadian dysfunction in various affective disorders, including depression, one of the approaches is the development of antidepressant drugs with melatonergic agonist properties. Agomelatine, with its melatonergic agonistic (at both MT(1) an MT(2) receptors) and 5-HT(2C) antagonistic properties, represents a new concept for the treatment of depression. The antidepressant action of agomelatine has been initially demonstrated in animal models of depression, such as the forced swim - the learned helplessness - and the chronic mild stress paradigms. Subsequent studies demonstrated that the antidepressant activity of agomelatine does not solely depend on its agonistic action at melatonergic receptors, but also on its antagonistic activity at 5-HT(2C) receptors. Agomelatine also exhibits anxiolytic properties that bear a striking resemblance to those of selective 5-HT(2C) receptor antagonists. In patients with major depressive disorder, agomelatine had efficacy at least comparable to that seen with available antidepressants. Interestingly, agomelatine demonstrated antidepressant efficacy not only in patients with a moderate depressive episode but also in a more severe depressed subpopulation of patients. The treatment effect increased with the severity of the disease. Agomelatine also rapidly regulates the sleep-wake cycle without causing sedation and improves daytime condition. Agomelatine has an excellent safety profile, is weight neutral, does not affect sexual functioning and does not cause discontinuation syndrome. Collectively, its efficacy, together with its excellent tolerability, makes agomelatine an especially promising antidepressant for the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07495-8 · Cited by 4,492 · cited 1×
“Severe depression is recognized as being associated with greater suffering and mortality, as well as with greater disability when compared to moderate depression (Kasper 1993; Murray and Lopez 1997 ).”
BackgroundSustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action
Tsankova, N. M., Berton, O., Renthal, W., Kumar, A., Neve, R. L., & Nestler, E. J. (2006) · Nature Neuroscience · doi:10.1038/nn1659 · Cited by 1,780
Chronic mild stress-induced anhedonia: A realistic animal model of depression
Willner, P., Muscat, R., & Papp, M. (1992) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(05)80194-0 · Cited by 1,160 · cited 1×
“Today, the chronic mild stress paradigm (Willner et al. 1992) is considered the most relevant animal model for providing evidence of antidepressant properties of a drug because it focuses on anhedonia, one of the key symptoms of depression (Mitchell and Redfern 2005).”
BackgroundRole of Melatonin in the Regulation of Human Circadian Rhythms and Sleep
Cajochen, C., Kräuchi, K., & Wirz‐Justice, A. (2003) · Journal of Neuroendocrinology · doi:10.1046/j.1365-2826.2003.00989.x · Cited by 735 · cited 1×
“Melatonin fulfils a pivotal role in the rhythm control of sleep (Borjigin et al. 1999; Cajochen et al. 2003) and can directly induce sleep when the internal drive is weak.”
BackgroundOhayon, M. M., & Shapiro, C. M. (2000) · Comprehensive Psychiatry · doi:10.1053/comp.2000.16568 · Cited by 483
Griebel, G., Simiand, J., Serradeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B., Maffrand, J.-P., & Soubrié, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092012099 · Cited by 471 · cited 2×
“Key words: Agomelatine, major depressive disorder, melatonergic receptors, 5-HT2C receptors”
BackgroundSouêtre, E., Salvati, E., Belugou, J.-L., Pringuey, D., Candito, M., Krebs, B., Ardisson, J.-L., & Darcourt, G. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90207-2 · Cited by 396
Antidepressants and Sleep: A Qualitative Review of the Literature
Wilson, S., & Argyropoulos, S. (2005) · Drugs · doi:10.2165/00003495-200565070-00003 · Cited by 392
Circadian Rhythm Mechanisms in Affective Illness and in Antidepressant Drug Action
Wehr, T., & Wirz-Justice*, A. (1982) · Pharmacopsychiatry · doi:10.1055/s-2007-1019506 · Cited by 256
Montgomery, S. A., Kennedy, S. H., Burrows, G. D., Lejoyeux, M., & Hindmarch, I. (2004) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000137184.64610.c8 · Cited by 196
Cited by
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development
de Bodinat, C., Guardiola-Lemaitre, B., Mocaër, E., Renard, P., Muñoz, C., & Millan, M. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3140 · Cited by 593
Serotonin in Animal Cognition and Behavior
Bacqué-Cazenave, J., Bharatiya, R., Barrière, G., Delbecque, J.-P., Bouguiyoud, N., Di Giovanni, G., Cattaert, D., & De Deurwaerdère, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051649 · Cited by 340
Novel melatonin-based therapies: potential advances in the treatment of major depression
Hickie, I. B., & Rogers, N. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60095-0 · Cited by 334
Circuit Mechanisms of Reward, Anhedonia, and Depression
Höflich, A., Michenthaler, P., Kasper, S., & Lanzenberger, R. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy081 · Cited by 253
Self-citationKasper, S., Hajak, G., Wulff, K., Hoogendijk, W. J. G., Montejo, A. L., Smeraldi, E., Rybakowski, J. K., Quera-Salva, M.-A., Wirz-Justice, A. M., Picarel-Blanchot, F., et al. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05347blu · Cited by 257
Self-citation
Metadata
- Authors
- Kasper, S., & Hamon, M.
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2009-01
- Volume
- 10
- Issue
- 2
- Pages
- 117-126
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W2121041697
- Cited by
- 119
- References
- 12
- FWCI
- 7.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Beyond the monoaminergic hypothesis: Agomelatine, a new antidepressant with an innovative mechanism of action. https://app.cochat.ai/papers/10.1080/15622970902717024
- The paper
- Kasper, S., & Hamon, M. (2009). Beyond the monoaminergic hypothesis: Agomelatine, a new antidepressant with an innovative mechanism of action. The World Journal of Biological Psychiatry. https://doi.org/10.1080/15622970902717024
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.